Activating transcription factor 2 (ATF2) is another protein with an oncogenic role in lung cancer and increases NRF2 expression following treatments with a group of drugs named BET inhibitors (BETi, with the ability to induce ferroptosis in breast cancer) in LUAD, leading to ferroptosis resistance (36). Here, NFE2L2 is linked to lung carcinoma.